Ankit Mangla, MD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 3909 Orange Pl (7 mi.)
Other Locations - Languages Spoken: English, Hindi
Office Locations
UH Seidman Minoff Health Center (7 mi.)
3909 Orange Pl
Ste 1100
Beachwood, OH 44122
216-896-1750
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
UH Seidman Avon Health Center (22 mi.)
2075 Healthway Dr
2nd Floor
Avon, OH 44011
440-517-9000
Biography: Ankit Mangla, MD
Expertise
Titles
- Co-Director, Sarcoma and Cutaneous Oncology Team, UH Seidman Cancer Center
- Assistant Professor, CWRU School of Medicine
Certifications & Memberships
- Medical Oncology - American Board of Internal Medicine
- Hematology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - John H Stroger, Jr Hospital Of Cook County (2015 - 2018)
Residency | Internal Medicine
Internal Medicine - John H Stroger, Jr Hospital Of Cook County (2012 - 2015)
Medical Education
Armed Forces Medical College, Maharashtra University Of Health Sciences (2007)
About
Ankit Mangla, MD, is a medical oncologist at University Hospitals Seidman Cancer Center with expertise in treating patients with melanoma and rare tumors such as Merkel cell cancer and soft tissue sarcoma. His specific areas of interest are the use of neoadjuvant immunotherapy in patients diagnosed with melanoma and drug development. He also serves as the Co-Director (Medical Oncology) of the sarcoma and melanoma disease teams.
Dr. Mangla earned his medical degree from Armed Forces Medical College in India and served in the Army Medical Corps of the Indian Army for five years. He completed a residency in internal medicine followed by a fellowship in hematology and oncology at the John H. Stroger Jr. Hospital of Cook County in Chicago, Illinois. Dr. Mangla joined University Hospitals/Case Western Reserve University in 2018. His philosophy for cancer treatment is developing a patient-centric treatment plan focusing on minimizing toxicity while achieving maximum efficacy.
As a clinical investigator at UH Seidman Cancer Center, Dr. Mangla serves as a principal investigator for several phase I, II and III clinical trials, focused on improving the treatment of melanoma and soft tissue sarcomas. Dr. Mangla has authored several research papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Oncology and JAMA Oncology. He was one of the investigators on the SWOG-1801 study studying the effects of neoadjuvant pembrolizumab in patients with melanoma. Conducted through the Southwest Oncology Group, this trial defined a new standard of care for patients with clinical stage 3 melanoma. Results of the trial were published in the New England Journal of Medicine.
Dr. Mangla participates in several oncology consortiums and actively contributes to drug development discussions. He is also an associate editor for Current Problems in Cancer: Case Reports and an editorial board member for Translational Oncology, Cancer Treatment and Research Communications, and World Journal of Clinical Cases. In addition, he has served as a reviewer for the Journal of Oncology Practice, Annals of Translational Oncology and Thoracic Cancers, among other peer-reviewed journals.
Dr. Mangla has been an invited lecturer, expert panelist and poster presenter at numerous annual meetings and conferences, including events hosted by the Multiple Myeloma Rounds, Midwest Melanoma and High-Risk Cancer Symposium, UH Seidman Cancer Center, American College of Physicians, American Society of Clinical Oncology, Society of General Internal Medicine, European Society of Medical Oncology, and European Congress of Internal Medicine. Dr. Mangla is a member of professional societies including the American College of Physicians, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Connective Tissue Oncology Society, and International Cardiology Oncology Society.
Featured Videos
Watch to find out more about this University Hospitals provider.
Patient Experience Reviews
All good
The doctor explained everything in detail so I understood what was going on and what to expect in the near future.
Very good experience
I wish I had found Dr. Mangla sooner! I have only recently moved to Ohio, and I feel so fortunate to have become a patient of his.
Dr. Mangla made me feel a whole lot better about my treatment going forward.
He gave good, clear explanations.
I really liked Dr. Mangla. He explained everything in a way that was very easy to understand and has very good patient friendly demeanor. I would highly recommend him.
Dr. Mangla explains and addresses my health concerns as long as it is directly related to my cancer or the immunotherapy treatments. Any concerns or issues outside of this I am referred to my PCP and that is not always feasible. I have no complaint with this provider though as he is a very good physician. ***
Accommodating and genuine.
I have had nothing but excellent care. I have no complaints.
We left the office with a binder of my disease. Everything was clearly explained to us. We didn't feel rushed at all and felt like the team worked hard at making us feel comfortable
Dr.Mangla us the best. He has literally saved my life.
I have been seeing him since 2018. I am a cancer patient with stage 4 cancer and he has taken very good care of me! I feel I have a great relationship with him and with having cancer that is very important.
Thanks UH
I felt much better after my condition was explained in person as opposed to reading about my condition via internet
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Ankit Mangla did not disclose any Outside Relationships with Industry.